No Cover Image

Journal article 296 views 34 downloads

Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD

Janaka Karalliedde, Kieran McCafferty, Peter Winocour, Tahseen A. Chowdhury, Naresh Kanumilli, Parijat De, Andrew H. Frankel, Ciara Doherty, Nicola Milne, Rosa M. Montero, Eirini Loudaki, Debasish Banerjee, Ritwika Mallik, Adnan Sharif, Sagen Zac-Varghese, Srikanth Bellary, Gabrielle Goldet, Ketan Dhatariya, Steve Bain Orcid Logo, Indranil Dasgupta

Kidney International Reports, Volume: 10, Issue: 10, Pages: 3318 - 3331

Swansea University Author: Steve Bain Orcid Logo

  • 70174.VOR.pdf

    PDF | Version of Record

    This is an open access article distributed under the terms of the Creative Commons CC-BY license.

    Download (1.32MB)

Check full text

DOI (Published version): 10.1016/j.ekir.2025.07.028

Abstract

A growing and significant number of people with diabetes develop chronic kidney disease (CKD) and diabetes related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hypergl...

Full description

Published in: Kidney International Reports
ISSN: 2468-0249
Published: Elsevier BV 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa70174
first_indexed 2025-08-12T09:28:55Z
last_indexed 2025-11-07T07:33:51Z
id cronfa70174
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2025-11-06T11:09:25.1636804</datestamp><bib-version>v2</bib-version><id>70174</id><entry>2025-08-12</entry><title>Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-08-12</date><deptcode>MEDS</deptcode><abstract>A growing and significant number of people with diabetes develop chronic kidney disease (CKD) and diabetes related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated reduction in composite kidney endpoint events (significant decline in kidney function, need for kidney replacement therapy and kidney related death) and cardiovascular risk with sodium glucose co-transporter-2 (SGLT-2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and glucagon-like peptide 1 (GLP-1) receptor agonists. The Association of British Clinical Diabetologists and UK Kidney Association Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD. This 2025 abbreviated updated guidance from a multidisciplinary group of healthcare professionals from primary and secondary care settings summarises the key recommendations and recent evidence that has implications for clinical practice for health care professionals who treat people with type 2 diabetes and CKD.</abstract><type>Journal Article</type><journal>Kidney International Reports</journal><volume>10</volume><journalNumber>10</journalNumber><paginationStart>3318</paginationStart><paginationEnd>3331</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2468-0249</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-10-01</publishedDate><doi>10.1016/j.ekir.2025.07.028</doi><url/><notes>Guidelines</notes><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders/><projectreference/><lastEdited>2025-11-06T11:09:25.1636804</lastEdited><Created>2025-08-12T10:27:20.4018188</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Janaka</firstname><surname>Karalliedde</surname><order>1</order></author><author><firstname>Kieran</firstname><surname>McCafferty</surname><order>2</order></author><author><firstname>Peter</firstname><surname>Winocour</surname><order>3</order></author><author><firstname>Tahseen A.</firstname><surname>Chowdhury</surname><order>4</order></author><author><firstname>Naresh</firstname><surname>Kanumilli</surname><order>5</order></author><author><firstname>Parijat</firstname><surname>De</surname><order>6</order></author><author><firstname>Andrew H.</firstname><surname>Frankel</surname><order>7</order></author><author><firstname>Ciara</firstname><surname>Doherty</surname><order>8</order></author><author><firstname>Nicola</firstname><surname>Milne</surname><order>9</order></author><author><firstname>Rosa M.</firstname><surname>Montero</surname><order>10</order></author><author><firstname>Eirini</firstname><surname>Loudaki</surname><order>11</order></author><author><firstname>Debasish</firstname><surname>Banerjee</surname><order>12</order></author><author><firstname>Ritwika</firstname><surname>Mallik</surname><order>13</order></author><author><firstname>Adnan</firstname><surname>Sharif</surname><order>14</order></author><author><firstname>Sagen</firstname><surname>Zac-Varghese</surname><order>15</order></author><author><firstname>Srikanth</firstname><surname>Bellary</surname><order>16</order></author><author><firstname>Gabrielle</firstname><surname>Goldet</surname><order>17</order></author><author><firstname>Ketan</firstname><surname>Dhatariya</surname><order>18</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>19</order></author><author><firstname>Indranil</firstname><surname>Dasgupta</surname><order>20</order></author></authors><documents><document><filename>70174__35565__02de9ac8a4ca492481792dbc38f44134.pdf</filename><originalFilename>70174.VOR.pdf</originalFilename><uploaded>2025-11-06T11:04:33.9421751</uploaded><type>Output</type><contentLength>1383413</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article distributed under the terms of the Creative Commons CC-BY license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2025-11-06T11:09:25.1636804 v2 70174 2025-08-12 Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2025-08-12 MEDS A growing and significant number of people with diabetes develop chronic kidney disease (CKD) and diabetes related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated reduction in composite kidney endpoint events (significant decline in kidney function, need for kidney replacement therapy and kidney related death) and cardiovascular risk with sodium glucose co-transporter-2 (SGLT-2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and glucagon-like peptide 1 (GLP-1) receptor agonists. The Association of British Clinical Diabetologists and UK Kidney Association Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD. This 2025 abbreviated updated guidance from a multidisciplinary group of healthcare professionals from primary and secondary care settings summarises the key recommendations and recent evidence that has implications for clinical practice for health care professionals who treat people with type 2 diabetes and CKD. Journal Article Kidney International Reports 10 10 3318 3331 Elsevier BV 2468-0249 1 10 2025 2025-10-01 10.1016/j.ekir.2025.07.028 Guidelines COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee 2025-11-06T11:09:25.1636804 2025-08-12T10:27:20.4018188 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Janaka Karalliedde 1 Kieran McCafferty 2 Peter Winocour 3 Tahseen A. Chowdhury 4 Naresh Kanumilli 5 Parijat De 6 Andrew H. Frankel 7 Ciara Doherty 8 Nicola Milne 9 Rosa M. Montero 10 Eirini Loudaki 11 Debasish Banerjee 12 Ritwika Mallik 13 Adnan Sharif 14 Sagen Zac-Varghese 15 Srikanth Bellary 16 Gabrielle Goldet 17 Ketan Dhatariya 18 Steve Bain 0000-0001-8519-4964 19 Indranil Dasgupta 20 70174__35565__02de9ac8a4ca492481792dbc38f44134.pdf 70174.VOR.pdf 2025-11-06T11:04:33.9421751 Output 1383413 application/pdf Version of Record true This is an open access article distributed under the terms of the Creative Commons CC-BY license. true eng http://creativecommons.org/licenses/by/4.0/
title Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
spellingShingle Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
Steve Bain
title_short Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
title_full Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
title_fullStr Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
title_full_unstemmed Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
title_sort Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Janaka Karalliedde
Kieran McCafferty
Peter Winocour
Tahseen A. Chowdhury
Naresh Kanumilli
Parijat De
Andrew H. Frankel
Ciara Doherty
Nicola Milne
Rosa M. Montero
Eirini Loudaki
Debasish Banerjee
Ritwika Mallik
Adnan Sharif
Sagen Zac-Varghese
Srikanth Bellary
Gabrielle Goldet
Ketan Dhatariya
Steve Bain
Indranil Dasgupta
format Journal article
container_title Kidney International Reports
container_volume 10
container_issue 10
container_start_page 3318
publishDate 2025
institution Swansea University
issn 2468-0249
doi_str_mv 10.1016/j.ekir.2025.07.028
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description A growing and significant number of people with diabetes develop chronic kidney disease (CKD) and diabetes related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated reduction in composite kidney endpoint events (significant decline in kidney function, need for kidney replacement therapy and kidney related death) and cardiovascular risk with sodium glucose co-transporter-2 (SGLT-2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and glucagon-like peptide 1 (GLP-1) receptor agonists. The Association of British Clinical Diabetologists and UK Kidney Association Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD. This 2025 abbreviated updated guidance from a multidisciplinary group of healthcare professionals from primary and secondary care settings summarises the key recommendations and recent evidence that has implications for clinical practice for health care professionals who treat people with type 2 diabetes and CKD.
published_date 2025-10-01T05:30:42Z
_version_ 1856805632647102464
score 11.096027

Similar Items